Entropy Technologies LP Buys New Stake in Humana Inc. (NYSE:HUM)

Key Points

• Entropy Technologies LP acquired 4,726 shares of Humana Inc., valued at approximately $1,250,000 in the first quarter, marking a new investment position in the healthcare insurance provider.
• Humana's stock saw a 0.2% increase on Tuesday, trading at $267.19, with a market cap of $32.13 billion and a notable earnings miss of $6.27 EPS for the most recent quarter.
• Analysts maintain mixed ratings on Humana, with seventeen holding a "hold" rating and seven issuing buy ratings, while price targets range from $260.00 to $315.00.

Entropy Technologies LP bought a new stake in Humana Inc. (NYSE:HUM - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,726 shares of the insurance provider's stock, valued at approximately $1,250,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Cary Street Partners Investment Advisory LLC increased its holdings in shares of Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after purchasing an additional 46 shares in the last quarter. Riverview Trust Co purchased a new stake in shares of Humana during the first quarter worth approximately $34,000. Garde Capital Inc. purchased a new position in shares of Humana during the first quarter worth approximately $36,000. Zions Bancorporation National Association UT acquired a new stake in shares of Humana during the first quarter worth $37,000. Finally, Transce3nd LLC purchased a new position in shares of Humana in the fourth quarter valued at $38,000. 92.38% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on HUM shares. Piper Sandler lowered their price objective on Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a research note on Thursday, July 31st. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $290.00 target price on shares of Humana in a report on Thursday, May 1st. Robert W. Baird cut their target price on Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research report on Friday, July 25th. Barclays set a $275.00 price objective on Humana and gave the company an "equal weight" rating in a research report on Thursday, July 31st. Finally, Bank of America decreased their price objective on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research note on Tuesday, June 17th. Eighteen research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $281.45.

Humana Trading Up 1.9%

Humana stock traded up $5.40 during trading hours on Friday, reaching $286.74. 1,270,506 shares of the company's stock traded hands, compared to its average volume of 1,733,415. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The firm has a market capitalization of $34.49 billion, a price-to-earnings ratio of 22.08, a PEG ratio of 1.66 and a beta of 0.44. The firm's 50 day moving average is $241.58 and its 200-day moving average is $253.94. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $382.72.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%. Humana's quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.96 earnings per share. On average, analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.